Bionter provides sub-visible particle testing solutions for the biotech drug product sector. Its first product is a fully automated, non-destructive particle counter supported by single-use consumables as well as maintenance and training. The solution is based on a new combination of light obscuration technology and smart automation and is designed to be compliant with current USP/EP/JP regulations. The company has completed development of its patented technology and planned a product launch at the end of May 2022. Bionter intends to use the funds to expand its team, launch its first solution in 2022, and accelerate development of its pipeline. The company is led by CEO Dr. Tobias Werk and is based in Riehen, Switzerland.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2022